| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 1047 |
| 1 | NIVOLUMAB | 603 |
| 2 | IPILIMUMAB | 417 |
| 3 | CARBOPLATIN | 359 |
| 4 | PACLITAXEL | 245 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 226 |
| 6 | DURVALUMAB | 150 |
| 7 | PEMETREXED DISODIUM | 129 |
| 8 | CISPLATIN | 105 |
| 9 | TREMELIMUMAB | 97 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREMELIMUMAB | 97 | 0.0219 |
| 1 | ADENINE | 1 | 0.0204 |
| 2 | ETRANACOGENE DEZAPARVOVEC | 1 | 0.0154 |
| 3 | NALDEMEDINE | 20 | 0.0120 |
| 4 | PEMBROLIZUMAB | 1047 | 0.0096 |
| 5 | IPILIMUMAB | 417 | 0.0095 |
| 6 | DURVALUMAB | 150 | 0.0070 |
| 7 | NIVOLUMAB | 603 | 0.0062 |
| 8 | SENNOSIDES A AND B | 10 | 0.0061 |
| 9 | MIGLITOL | 5 | 0.0052 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1683 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 514 |
| 2 | Platinum-based Drug [EPC] | 508 |
| 3 | Microtubule Inhibitor [EPC] | 251 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 151 |
| 5 | Kinase Inhibitor [EPC] | 129 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 77 |
| 7 | Proton Pump Inhibitor [EPC] | 68 |
| 8 | Corticosteroid [EPC] | 67 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 67 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1683 | 0.0171 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 514 | 0.0107 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 151 | 0.0070 |
| 3 | Platinum-based Drug [EPC] | 508 | 0.0019 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 11 | 0.0017 |
| 5 | Microtubule Inhibitor [EPC] | 251 | 0.0015 |
| 6 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 3 | 0.0014 |
| 8 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 12 | 0.0014 |
| 9 | alpha-Glucosidase Inhibitor [EPC] | 5 | 0.0010 |